Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Benzinga Newsdesk www.benzinga.com Positive 85.1%

Neg 0% Neu 0% Pos 85.1%

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $537 to $575.